Table 3.
Risk of prostate cancer death and PSA relapse by statin use after ADT initiation in a cohort of prostate cancer patients treated with ADT.
| Risk of prostate cancer death | |||||
|---|---|---|---|---|---|
| No of participants/deaths | Age-adjusted | Multivariable adjusted | 1-year lag-time | 3-year lag-time | |
| Statin use after ADT | HR (95% CI) | HR (95% CI)* | HR (95% CI)* | HR (95% CI)* | |
| None | 2707/582 | Reference | Reference | Reference | Reference |
| Any | 1721/252 | 0.68 (0.59–0.80) | 0.82 (0.69–0.96) | 0.89 (0.76–1.04) | 0.90 (0.77–1.06) |
| Intensity of statin use (DDDs/year) | |||||
| First tertile (below 92 DDD/year) | 574/160 | 0.83 (0.61–1.14) | 0.94 (0.69–1.29) | 0.99 (0.71–1.37) | 0.86 (0.58–1.29) |
| Second tertile (92–210 DDD/year) | 572/70 | 0.60 (0.47–0.75) | 0.67 (0.53–0.84) | 0.73 (0.57–0.93) | 0.87 (0.67–1.15) |
| Third tertile (above 210 DDD/year) | 575/22 | 0.48 (0.37–0.63) | 0.58 (0.44–0.76) | 0.88 (0.69–1.14) | 0.93 (0.68–1.26) |
| Risk of PSA relapse | |||||
| Statin use after ADT | No of participants/PSA relapses | Age-adjusted | Multivariable adjusted* | 1-year lag-time | 3-year lag-time |
| None | 2707/957 | Reference | Reference | Reference | Reference |
| Any | 1721/608 | 0.65 (0.58–0.72) | 0.73 (0.65–0.82) | 0.85 (0.76–0.95) | 0.97 (0.86–1.09) |
*Calculated using Cox regression with adjustment for age, tumor risk group, randomization group, use of other medication (antidiabetic and antihypertensive drugs, NSAIDs), and whether participants received radiation therapy in addition to ADT.